Table 4 Cost-benefit analysis of prophylaxis in respect to HBV reactivation by “Diagnosis Related Group” system in our 48 HBcAb positive HBsAg negative patients treated with Rituximab
Unitary cost | n. patients | Total per patient | Duration [days] | Total | |
|---|---|---|---|---|---|
Cost of prophylaxis | |||||
Lamivudine | € 3,18 | 48 | € 152,64 | 360 | € 54.950,40 |
HBV DNA monitoring | € 130,00 | 48 | € 6.240,00 | 6 | € 37.440,00 |
HBsAg monitoring | € 17,00 | 48 | € 816,00 | 6 | € 4.896,00 |
AST/ALT monitoring | € 5,74 | 48 | € 275,52 | 12 | € 3.306,24 |
Total | € 155,92 | 48 | € 7.484,16 | € 100.592,64 | |
Cost of HBV Reactivation | |||||
HBV DNA monitoring | € 130,00 | 48 | € 6.240,00 | 6 | € 37.440,00 |
AST/ALT monitoring | € 5,74 | 48 | € 275,52 | 12 | € 3.306,24 |
Cost of DRG 205 [v24 Grouper] | € 3.769,10 | 5 | - | - | € 18.845,50 |
Total | € 3.904,84 | - | - | - | € 40.746,24 |